Evidence map›Paper›PMID 27987040›Full record

Trial reportThe international journal of cardiovascular imaging2017

Lipid-lowering therapy stabilizes the complexity of non-culprit plaques in human coronary artery: a quantitative assessment using OCT bright spot algorithm.

Yoshiyasu Minami, Taylor Hoyt, Jennifer E Phipps, Thomas E Milner, Lei Xing, Hang Lee, Bo Yu, Marc D Feldman, Ik-Kyung Jang

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The international journal of cardiovascular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Cardiovascular imaging 2017 in the International Journal of Cardiovascular Imaging.The international journal of cardiovascular imaging · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Yoshiyasu MinamiCardiology Division, Massachusetts General Hospital, Harvard Medical School, GRB 800, 55 Fruit street, Boston, MA, 02114, USA.
Taylor HoytUniversity of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
Jennifer E PhippsUniversity of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
Thomas E MilnerDepartment of Biomedical Engineering, University of Texas, 107 W Dean Keeton Street Stop, Austin, TX, 78712, USA.
Lei XingCardiology Division, Massachusetts General Hospital, Harvard Medical School, GRB 800, 55 Fruit street, Boston, MA, 02114, USA.
Hang LeeBiostatistics Center, Massachusetts General Hospital, Harvard Medical School, 50 Staniford Street, Boston, MA, 02114, USA.
Bo YuDepartment of Cardiology, The 2nd Affiliated Hospital of Harbin University, 246 Xuefu Road, Nangang District, Harbin, 150086, China.
Marc D FeldmanUniversity of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
Ik-Kyung JangCardiology Division, Massachusetts General Hospital, Harvard Medical School, GRB 800, 55 Fruit street, Boston, MA, 02114, USA. IJANG@mgh.harvard.edu.
The University of Texas Health Science Center at San Antonio · USHarvard University · USHarbin University · CNKyung Hee University · KRMassachusetts General Hospital · USThe University of Texas at Austin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To quantitatively evaluate the change of plaque complexity with cholesterol lowering therapy. A total of 44 non-culprit plaques from 30 patients who had serial image acquisition at baseline, 6-months, and 12-months by both optical coherence tomography (OCT) and intravascular ultrasound (IVUS) were included. Patients were treated with atorvastatin 60 mg (AT60, n = 16) or 20 mg (AT20, n = 14). We applied an OCT bright spot algorithm, which identifies a variety of plaque components including macrophages. The density of bright spot was measured within the superficial 250 µm of the vessel wall. Significant reduction of bright spot density was observed from baseline to 12-months [-0.49% (-0.95, -0.20), p < 0.001], particularly during the second 6 months [first 6 months: -0.01% (-0.57, 0.60), p = 0.939; second 6 months: -0.49% (-0.98, 0.14), p < 0.001]. Although there was no significant difference at 12 months in the reduction of bright spot density between plaques with acute coronary syndrome (ACS, n = 33) and those with stable angina (n = 11) [-0.49% (-0.93, -0.19) vs. -0.39% (-1.01, -0.21), p = 0.748], a significant reduction of bright spot density during the first 6 months was observed only in plaques with ACS. There was no significant difference in the change of bright spot density between the AT60 group (n = 22) and AT20 group (n = 22) [-0.61% (-0.93, -0.34) vs. -0.41% (-0.98, -0.19), p = 0.483]. Coronary plaque complexity evaluated by a quantitative OCT algorithm significantly decreased with 12 month atorvastatin therapy irrespective of the dose and initial clinical presentation.

Indexed as

AlgorithmsImage Interpretation, Computer-AssistedPlaque, AtheroscleroticTomography, Optical CoherenceAgedAtorvastatinCoronary Artery DiseaseCoronary VesselsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPredictive Value of TestsTime FactorsTreatment OutcomeAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsAcute coronary syndromeOptical coherence tomographyPlaque ruptureStable coronary artery disease

Identifiers

PMID27987040
OpenAlexW2567183604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.